Diseases & Diagnoses
Choose any area of neurology to see curated news, articles, case reports, and more on that topic.
Patients & Caregivers
Find information and tools about neurological diseases to assist patients and caregivers.
The first patient has been enrolled in a phase 3 study (NCT03701399) of troriluzole (Biohaven, New Haven, CT) to treat spinocerebellar ataxia (SCA). The primary outcome measure of the trial is improvement of symptoms as measured by a decreased score on the Modified Scale for the Assessment and Rating of Ataxia (SARA). The study plan is to include approximately 230 participants at approximately 22 clinical sites. Participants will be randomly assigned to receive 200 mg troriluzole or placebo daily for 48 weeks.
To be eligible to enroll, patients must:
Post-hoc data from an earlier phase 2b/3 study (NCT02960893) suggest patients with SCA types 1, 2, 3 or 6 treated with troriluzole for 48 weeks had slightly slower disease progression (-.34 points, 95% CI: -0.94-0.26) compared with untreated patients in a natural history cohort (+1.07 points, 95% CI: -2.22—0.60; P = .0007). In this analysis, treated and untreated patients were matched by age, sex, baseline SARA score, and SARA gait subscore.
Gil L'Italien, PhD, Head of Global Health Economics and Outcomes Research at Biohaven stated, "The findings . . . are encouraging and provide further support for the potential long-term therapeutic benefit of troriluzole in patients with SCA. We are thrilled to have now enrolled the first patient in the Phase 3 study, which will more fully test the therapeutic potential of troriluzole in treating SCA over the course of 1 year."